CN115505575A - Two hybridoma cell strains capable of secreting canine IL-31 monoclonal antibody and application thereof - Google Patents
Two hybridoma cell strains capable of secreting canine IL-31 monoclonal antibody and application thereof Download PDFInfo
- Publication number
- CN115505575A CN115505575A CN202211463230.2A CN202211463230A CN115505575A CN 115505575 A CN115505575 A CN 115505575A CN 202211463230 A CN202211463230 A CN 202211463230A CN 115505575 A CN115505575 A CN 115505575A
- Authority
- CN
- China
- Prior art keywords
- antibody
- canine
- monoclonal antibody
- hybridoma cell
- tibgao
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/91—Cell lines ; Processes using cell lines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
- G01N2800/202—Dermatitis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Abstract
The invention discloses two hybridoma cell strains combined with a canine IL-31 monoclonal antibody and application thereof. The preservation number of the hybridoma cell strain TIBGAO-2D10-2 is as follows: CGMCC No.45175, and the preservation number of the hybridoma cell strain TIBGAO-1C6 is as follows: CGMCC No.45174, both can secrete monoclonal antibody binding to canine IL-31. The invention establishes a double-antibody sandwich ELISA detection method by taking an antibody which is subjected to ascites purification after a hybridoma cell strain TIBGAO-2D10-2 is injected into a mouse as a capture antibody and an antibody which is labeled by biotin and is subjected to ascites purification after the hybridoma cell strain TIBGAO-1C6 is injected into the mouse as a detection antibody. The method has the advantages of simple and quick operation and clear result, provides a new method for in vitro diagnosis of the atopic dermatitis of the dog, and has application value.
Description
Technical Field
The invention belongs to the field of veterinary medicine and medical biology, and particularly relates to two hybridoma cell strains secreting canine IL-31 monoclonal antibodies and application thereof.
Background
Atopic Dermatitis (AD) is an inflammation that causes allergic itching of the skin. In dogs, AD can cause severe itching, accompanied by secondary alopecia and erythema. There are approximately 450 million dogs worldwide with this chronic lifelong illness. The incidence of disease also increases year by year.
Interleukin-31 (IL-31) is a cytokine that was cloned in 2004. It is produced mainly by activated T helper cells (Th 2). As a neuromodulator, plays an important role in skin inflammation and itch. IL-31 binds to a heterodimer consisting of IL-31 receptor alpha (IL-31 RA) and Oncoinhibin M receptor beta (OSMR beta), and IL-31 signaling activates three important signaling pathways: janus kinase (JAK)/activator of transcription (STAT), phosphoinositide 3-kinase (P13K)/AKT and mitogen kinase (ERK)/MAPK, resulting in cellular biological changes. These changes include immune cell chemotaxis, secretion of pro-inflammatory cytokines and chemokines, cutaneous pruritic responses, and disruption of the skin barrier due in part to cell proliferation, differentiation. The expression of IL-31 is obviously increased in AD patients, and can induce chemokines CCL1, CCL17 and CCL22. These chemokines recruit more T cells to the infected skin, thereby secreting more IL-31. Researchers have found that the IL-31RA/OSMR β co-receptor is expressed in macrophages, mast cells, eosinophils, basophils, keratinocytes and the dorsal root ganglia of peripheral neurons [ Gibbs BF, patsinakidis N, raap U.LE of the clinical cytokine IL-31in autoimmune skin diseases. Front Immunol. 2019.
IL-31 is involved in dermatitis, pruritic lesions, allergies and respiratory allergies. IL-31 is produced in increased amounts in pruritic skin areas and can induce scratching behavior in various species, such as mice, monkeys, and dogs. It has been shown that IL-31 induces strong pruritic behaviour in dogs within minutes to hours when administered intradermally, subcutaneously or intravenously. Transgenic mice overexpressing IL-31 develop skin inflammation, itching, severe dermatitis, and hair loss. Subcutaneous injection of IL-31 causes infiltration of inflammatory cells, neutrophils, eosinophils, lymphocytes and macrophages, resulting in thickening of the epidermis and hyperplasia of the dermis. Further studies have shown that IL-31 is associated with skin inflammation and itching caused by atopic dermatitis in humans [ Lai T, wu D, li W, et al. Interleukin-31expression and relationship to distease sensitivity in human asthma. Sci Rep. 2016 (1): 22835.; west NR, hegazy AN, owens BMJ, et al. Oncostatin M driving specific information and prediction response to tissue roughness factor-neutral inflammation. Nat Med. 2017 (5): 579-589.].
At present, the companies have developed therapeutic drugs aiming at the signaling caused by canine IL-31, such as JAK small molecule inhibitor Epoke and canine IL-31 monoclonal antibody drug Cytopoint, which are introduced by Shuiteng. However, these drugs for IL-31 signaling are expensive and require precise treatment, so that blind use can be avoided and the cost of pet owners can be reduced. In addition, it has been found that atopic dermatitis can be prevented by inoculating an in vitro recombinant IL-31 as a vaccine into an animal in a small amount and a plurality of times [ Olomski F, fettlschoss V, jonsdottir S, et al. Interleukin 31in inducing high sensitivity-inducing closed mechanical systems by active vaccination, allergy 2020 Apr 75 (4): 862-871 ]. Accurate symptomatic treatment of the atopic dermatitis of the dogs caused by the IL-31, yield determination of the recombinant canine IL-31 protein in an expression system and the like need to be matched with corresponding IL-31 detection reagents.
Disclosure of Invention
The first purpose of the invention is to provide two hybridoma cell strains for secreting monoclonal antibodies of canine IL-31, namely a hybridoma cell strain TIBGAO-2D102 and a hybridoma cell strain TIBGAO-1C6. Has been preserved in China general microbiological culture Collection center (address No. 3 of Xilu No. 1 of Beijing Kogyo area, china) at 26.5.2022, wherein the preservation number of the hybridoma cell strain TIBGAO-2D102 is CGMCC No.45175, and the preservation number of the hybridoma cell strain TIBGAO-1C6 is CGMCC No.45174.
The second purpose of the invention is to provide two monoclonal antibodies, 2D102 and 1C6, which are combined with canine IL-31, and the two antibodies are respectively secreted and produced by the two hybridoma cell strains. ELISA results show that the two monoclonal antibodies can be specifically combined with the canine IL-31 protein.
The invention provides application of the monoclonal antibody in detection or diagnosis of related diseases caused by canine IL-31.
Specifically, the canine IL-31-associated disease is atopic dermatitis with symptoms of pruritus, skin lesions, erythema and allergy. Preferably, the detection method is a double antibody sandwich ELISA detection method.
The invention also provides application of the monoclonal antibody in preparation of preparations for detecting the IL-31 protein of the dog.
The fifth purpose of the invention is to provide a double antibody sandwich ELISA detection kit, which is used for a double antibody sandwich ELISA detection method and comprises a monoclonal antibody 2D102 which is secreted by a hybridoma cell strain TIBGAO-2D102 and is combined with canine IL-31, and a biotin-labeled monoclonal antibody 1C6 which is secreted by a hybridoma cell strain TIBGAO-1C6 and is combined with canine IL-31.
Specifically, monoclonal antibody 2D102 secreted by hybridoma cell strain TIBGAO-2D102 is used as a capture antibody, and monoclonal antibody 1C6 which is labeled by biotin and is secreted by hybridoma cell strain TIBGAO-1C6 is used as a detection antibody.
Preferably, in the above-mentioned double antibody sandwich ELISA detection method, the capture antibody is coated on the ELISA plate, the optimal coating amount of the capture antibody is 2 μ g/well, and the working concentration of the detection antibody is 2 μ g/ml.
Compared with the prior art, the invention has the following beneficial effects:
1. monoclonal antibodies 2D102 and 1C6 bind to canine IL-31, have higher affinity and slower off-rate than the marketed caninized antibody Cytopoint which binds to canine IL-31, and are useful in the diagnosis of canine IL-31 or diseases associated with IL-31, as well as the detection of the production of canine IL-31 protein in different expression systems, and in laboratory assays for canine IL-31.
2. The two hybridoma cell strains can stably secrete the monoclonal antibodies, the pairing effect of the two secreted antibodies is good, and the method is suitable for the double-antibody sandwich ELISA detection method.
3. The two antibodies secreted by the two hybridoma cell strains are not interfered by canine serum by double antibody sandwich ELISA, and have higher sensitivity when being used for detecting canine IL-31 related diseases.
4. The mouse hybridoma cell strain and the monoclonal antibody secreted by the mouse hybridoma cell strain have important application prospects in the aspects of development of canine IL-31 detection reagents and development of disease diagnosis reagents related to canine IL 31.
5. The double-antibody sandwich ELISA provided by the invention has the advantages of simple operation, clear result and the like.
Drawings
FIG. 1 shows that antibodies 2D102 (A) and 1C6 (B) of the present invention prepared from two hybridoma cells (TIBGAO-2D102, TIBGAO-1C 6) via ascites were respectively Superdex TM 200 Purifying by 10/30 GL molecular sieve chromatography;
FIG. 2 is a graph showing the ELISA binding of two antibodies prepared according to the present invention and a caninized antibody Cytopoint to recombinant canine and feline IL-31, respectively. Wherein, A is the combination of 2D102, 1C6, cytopoint and irrelevant control antibody and recombinant canine IL-31 protein, B is the combination of 2D102, 1C6 and irrelevant control antibody and recombinant feline IL-31 protein;
FIG. 3 shows the affinity of two antibodies 2D102 and 1C6 obtained by purifying ascites in mice and the commercial Cytopoint antibody to recombinant canine IL-31, as determined by surface plasmon resonance. Wherein A is the binding constant (ka) of the three antibodies to recombinant canine IL-31; b is the dissociation constant (kd) of the three antibodies to recombinant canine IL-31; c is the affinity constant (KD) of the three antibodies to recombinant canine IL-31. All results are statistical values of the data of the triplicate experiments. Wherein denotes p <0.05, denotes p <0.01, denotes p <0.001.
FIG. 4 is a binding diagram of sandwich ELISA of two antibodies obtained by purifying ascites fluid of mice from two hybridoma cells according to the present invention. Wherein, A shows that 2D102 is an immobilized antibody, and biotin-labeled 1C6 is a detection antibody; b shows that 1C6 is an immobilized antibody and biotin-labeled 2D102 is a detection antibody;
FIG. 5 shows the concentration of recombinant canine IL-31 detected by the double antibody sandwich ELISA method applied in the present invention. Wherein, A is a standard curve made after the recombinant canine IL-31 with different concentrations obtained by diluting PBS is detected by using the double-antibody sandwich ELISA method of the invention; b is a standard curve made by using a double-antibody sandwich ELISA method to detect different concentrations of recombinant canine IL-31 diluted by canine serum (the recombinant canine IL-31 is detected to be negative by a commercial kit).
Biological material preservation information:
the mouse hybridoma cell strain TIBGAO-1C6 is preserved in China general microbiological culture Collection center (CGMCC), and the preservation unit is abbreviated as CGMCC, and the address is as follows: western road No. 1, north chen west road, north kyo, chaoyang, institute of microbiology, china academy of sciences, zip code 100101. The preservation date is 2022 years, 5 months and 26 days, and the preservation number is CGMCC No.45174; the classification of the strain is named: mouse hybridoma cells.
The mouse hybridoma cell strain TIBGAO-2D102 is preserved in China general microbiological culture Collection center (CGMCC), the preservation unit is CGMCC for short, and the address is as follows: western road No. 1, north chen west road, north kyo, chaoyang, institute of microbiology, china academy of sciences, zip code 100101. The preservation date is 2022 years, 5 months and 26 days, and the preservation number is CGMCC No.45175; the classification of the strain was named: mouse hybridoma cells.
Detailed Description
To further illustrate the technical means and effects of the present invention, the following detailed description is given to further illustrate the technical solutions of the present invention with reference to the accompanying drawings, and all reagents used in the examples are commercially available or can be prepared according to texts or known methods.
EXAMPLE 1 preparation and purification of murine monoclonal antibodies
The purified recombinant canine IL-31 protein was used as an antigen to immunize female BALB/c mice for 6-8 weeks in five subcutaneous multiple spots. The immunization dose is 30 mug/time, and the interval time of the first four immunizations is 14 days. For the first immunization, freund's complete adjuvant is used; freund's incomplete adjuvant was used for the 2 nd to 4 th immunization. On the 7 th day after the 3 rd immunization, tail vein blood is taken to detect the titer of the serum antibody, and the mouse with the highest titer is selected for fusion. The spiking immunization was performed 3 days before the fusion, i.e., the fifth immunization, in which 100. Mu.g of the immunization stock was injected into the abdominal cavity of the mouse. The spleen cells and myeloma cells SP2/0 of the mice were taken as follows: 1 ratio, selectively culturing in HAT screening culture medium, and limiting dilution to obtain hybridoma cell strain. Recombinant canine IL-31 is coated in an enzyme label plate at 25 ng/hole by using a carbonate buffer solution with the pH value of 9.6, 15 monoclonal antibody cell strains with higher antigen binding capacity are screened by using an ELISA method, and the 15 monoclonal antibody strains are subjected to competitive ELISA pairing to obtain two monoclonal antibodies, namely 2D102 and 1C6, which have the competitive binding with the canine IL-31.
The preparation of monoclonal antibody is carried out by using retired BALB/c mouse. First, the adjuvant special for ascites was injected intraperitoneally at 0.4 ml/tube. Hybridoma cells were injected intraperitoneally 10-14 days after adjuvant inoculation, with an inoculation dose of 30 ten thousand cells/cell. 10-15 days after cell injection, ascites from mice were collected, enriched and purified for IgG by Protein A, and then passed through Superdex TM 200 Further purification with 10/300 GL molecular sieves to obtain homogeneous 2D102 and 1C6 IgG proteins, which showed IgG peaking at 16-17 ml (FIG. 1)The compounds of (A) and (B). SDS-PAGE showed that these two antibodies were approximately a 50 kDa heavy chain and a 25 kDa light chain under reducing conditions (dithiothreitol, + DTT, in FIG. 1). Under non-reducing conditions (loading buffer without DTT, -DTT), the heavy and light chains are linked by disulfide bonds to form a heterodimer of tetrapeptide chain molecules, i.e., igG, with a molecular weight of 150 kDa (A, B in FIG. 1).
EXAMPLE 2 determination of the binding Activity of monoclonal antibodies to recombinant canine IL-31 and recombinant feline IL-31
The purified recombinant canine IL-31 and recombinant feline IL-31-Fc fusion proteins were immobilized on 96-well ELISA plates using a carbonate coating solution pH9.6, 200 ng/well, overnight at 4 ℃ by an indirect ELISA method. Then, the microplate was placed at room temperature, shaken for 30 min to return to room temperature, the liquid in the microplate was discarded, and washed three times with PBS for 5 min each time. Then, blocking solution (PBS +2% BSA) was added and incubated for 1 h on a shaker. The 96-well plate was washed three times with PBST (PBS +0.05% Tween-20), 5 min each. Subsequently, different dilution concentrations of monoclonal antibody were added, 100. Mu.l/well, at room temperature, and shaken on a shaker for 1 h. The plate was washed three times with PBST for 5 min each. Then, HRP-labeled goat anti-mouse IgG or rabbit anti-dog IgG diluted 1. Washing the enzyme-linked plate with PBST for three times, adding TMB, developing for about 5 min, and adding 2M H 2 SO 4 The reaction was terminated. Readings were taken with a microplate reader at a wavelength of 450 nm. The results show that 2D102 binds specifically to recombinant canine IL-31, EC 50 0.01. Mu.g/ml, 1C6 specifically binds to the recombinant canine IL-31 protein, EC 50 0.02 μ g/ml, cytopoint and recombinant canine IL-31 protein EC 50 0.14. Mu.g/ml (A in FIG. 2). While both 2D102 and 1C6 did not bind to the recombinant feline IL-31-Fc fusion protein (B in FIG. 2). The results show that the antibodies secreted by the two hybridoma cell strains can be specifically combined with the recombinant canine IL-31 protein, and the binding force is higher than that of the commercialized antibody Cytopoint.
Example 3 binding kinetics assay of monoclonal antibodies to recombinant canine IL-31
Method for measuring antibody by surface plasmon resonance and method for measuring antibody by surface plasmon resonanceKinetic parameters of antigen binding. First, SA was immobilized on the surface of a CM5 chip by means of amino coupling, and then biotin-labeled recombinant canine IL-31 was immobilized on the chip by binding to SA. The immobilized recombinant canine IL-31 protein was then bound to different concentrations of 2D102, 1C6 and Cytopoint antibodies as the mobile phase. As shown in FIG. 3 and Table 1, the binding constants (ka) of 2D102, 1C6 and Cytopoint were close to each other and 1.27. + -. 0.02X 10 5 M -1 s -1 、1.64±（0.41）×10 5 M -1 s -1 And 1.78 + - (0.89). Times.10 5 M -1 s -1 . The kinetics of dissociation of 2D102 and 1C6 binding to recombinant canine IL-31 were such that the dissociation constants (kd) were 8.58 + - (6.18). Times.10, respectively -7 s -1 And 2.93 + - (1.42). Times.10 -6 s -1 . The dissociation constant of Cytopoint antibody is 1.22 + - (0.45) × 10 -4 s -1 . The rate of re-dissociation of the commercial antibody Cytopoint after binding to antigen is significantly different compared to 2D102, 1C6 (p)<0.05 Indicating that the dissociation rate of the bound Cytopoint and antigen is faster than that of the two antibodies of the present invention. The affinity constants (KD) of 2D102, 1C6 and Cytopoint with recombinant canine IL-31 are respectively 6.81 + - (4.96) x 10 -12 M、2.80±（1.55）×10 -11 M and 8.28 + - (3.01) × 10 -11 And M. The affinity KD value of the 2D102 and the recombinant canine IL-31 has significant difference (p) compared with that of the commercialized antibody Cytopoint<0.05 Indicating that the antibody binds to the antigen with higher affinity than to Cytopoint.
TABLE 1 detailed values after statistics of the ka, KD and KD data of three tests
The results show that 2D102 and 1C6 and recombinant canine IL-31 are fast binding, slow dissociation mode, and compared with the commercial antibody Cytopoint, in the dissociation rate of higher advantage. And 2D102 has a higher affinity compared to Cytopoint.
Example 4 establishment of double antibody Sandwich ELISA method
A monoclonal antibody is immobilized on an ELISA plate with 96 holes by carbonate coating liquid with pH9.6, and the optimal immobilization amount of the capture antibody is 2 mug/hole and stays overnight at 4 ℃ by verification. The ELISA plate was then placed at room temperature, shaken for 30 min to return to room temperature, the liquid in the ELISA plate was discarded, and washed three times with PBS for 5 min each time. Then, blocking solution (PBS +2% BSA) was added and incubated for 1 h on a shaker. The 96-well plates were washed three times with PBST for 5 min each. Subsequently, 2. Mu.g/ml of recombinant canine IL-31 as a detection antigen was added to the microplate at 100. Mu.l/well at room temperature, and shaken on a shaker for 1 h. ELISA plates were washed three times with PBST for 5 min each. Then adding another monoclonal antibody of biotin mark with different concentration gradient, 100 mul/hole, shaking table for 1 h at room temperature. The microplate was washed three times with PBST for 5 min each. Then, 1. After the microplate was washed three times with PBST, TMB was added to 50. Mu.l of each well and developed for about 5 min, and then 2M H was added to 50. Mu.l of each well 2 SO 4 The reaction was terminated. Readings were taken with a microplate reader at a wavelength of 450 nm. The results show that when 2D102 is the capture antibody and biotin-labeled 1C6 is the detection antibody, the value of OD450 increases with increasing 1C6 concentration (a in fig. 4). Similarly, when 1C6 was used as the capture antibody and biotin-labeled 2D102 was used as the detection antibody, the OD450 value increased with the increase in the concentration of 2D102 (fig. 4B). These results indicate that the two monoclonal antibodies 2D102 and 1C6 do not bind to the same epitope as canine IL-31, and that there is no competitive binding between these two antibodies to canine IL-31. According to the detection result of the double-antibody sandwich ELISA, the optimal working concentration of the two paired antibodies is also determined, namely the optimal coating amount of the capture antibody is 2 mug/hole, and the optimal working concentration of the biotin-labeled detection antibody is 2 mug/ml.
Example 5 determination of detection line for double antibody sandwich ELISA
In this example, the lowest detection value for canine IL-31 detected by this method was determined using the double antibody sandwich ELISA method determined in example 3. First, capture antibody 2D102 was immobilized with a coating solution at 2. Mu.g/well overnight at 4 ℃. Then, the solution was blocked with a blocking solution for 1 hour. Then, a solution diluted with PBS was addedThe concentrations of recombinant canine IL-31 protein were 25.6 ng/ml,12.8 ng/ml,6.4 ng/ml,3.2 ng/ml,1.6 ng/ml, 0.8 ng/ml,0.4 ng/ml, and 0.2 ng/ml, respectively. 100 μ l/well, room temperature, shaking for 1 h. The ELISA plates were washed three times with PBST, 5 min each time. Then 2. Mu.g/ml biotin-labeled 1C6 detection antibody was added at 100. Mu.l/well, and the mixture was shaken in a shaker at room temperature for 1 hour. The plate was washed three times with PBST for 5 min each. Then, 1:10000 dilutions of HRP-labeled streptavidin were shaken on a shaker at room temperature for 1 h. Washing the enzyme-linked plate with PBST for three times, adding 100. Mu.l TMB into each well, developing for about 5 min, and adding 100. Mu.l H into each well 2 SO 4 (2M) the reaction was terminated. Readings were taken with a microplate reader at a wavelength of 450 nm. The result shows that when the concentration interval of the canine IL-31 protein is 0.2 to 25.6 ng/ml, the detection result of the double-antibody sandwich ELISA method established by the invention is in a linear relation with the concentration of the canine IL-31 protein, so that a standard curve is drawn, and the standard curve equation is y = -0.0037x 2 +0.1891x+0.0731，R 2 =0.9973. The lowest detected canine IL-31 concentration was 400 pg/ml (OD 450 of 0.13).
To determine whether the double antibody sandwich ELISA method established in this invention has background or interference caused by serum itself when determining clinical canine serological samples, canine serum (negative for recombinant canine IL-31 by commercial kits) was used in this invention, instead of PBS buffer, as a diluent, recombinant canine IL-31 protein was added at final concentrations of 25 ng/ml, 12.5 ng/ml,6.25 ng/ml,3.125 ng/ml,1.56 ng/ml,0.78 ng/ml, and 0.39 ng/ml, respectively. Then, the response value of the samples is measured by using the double-antibody sandwich ELISA method established by the invention. The result is shown in B in figure 5, the detection result of the double-antibody sandwich ELISA method established by the invention is still in a linear relation with the concentration of the recombinant canine IL-31 protein diluted by the canine serum, and the standard curve equation is y = -0.0044x 2 +0.2063x+0.1097，R 2 =0.9918. The lowest detected concentration of recombinant canine IL-31 was 390.6 pg/ml (OD 450 value of 0.1). The results show that the results obtained by using the canine serum as the diluent (B in figure 5) are consistent with the results obtained by using the PBS as the diluent (A in figure 5), and prove that the double-antibody sandwich ELISA method established by the invention is not interfered by the canine serum and has the advantages ofAnd (4) better sensitivity.
Claims (14)
1. A hybridoma cell strain TIBGAO-2D102 with a preservation number of: CGMCC No.45175.
2. A monoclonal antibody that binds canine IL-31, said monoclonal antibody being secreted from the hybridoma cell strain TIBGAO-2D102 of claim 1.
3. A hybridoma cell strain TIBGAO-1C6 with a preservation number of: CGMCC No.45174.
4. A monoclonal antibody that binds canine IL-31, said monoclonal antibody being secreted from the hybridoma cell strain TIBGAO-1C6 of claim 3.
5. The use of the monoclonal antibody of claim 2 or 4 for the preparation of a reagent for detecting or diagnosing a disease associated with canine IL-31.
6. The use according to claim 5, wherein the canine IL-31 associated disease is atopic dermatitis with symptoms of pruritus, lesions, erythema, and allergy.
7. The use of claim 6, wherein the related disease is detected by a double antibody sandwich ELISA assay.
8. Use of the monoclonal antibody of claim 2 or 4 in the preparation of a formulation for detecting recombinant canine IL-31 protein.
9. The use of claim 8, wherein the sample is assayed for canine IL-31 by an enzyme-linked immunosorbent assay.
10. The use according to claim 8 for the quantitative determination of canine IL-31 protein expressed in mammalian cells, e.coli, yeast at various stages of miniprep, pilot.
11. A double antibody sandwich kit comprising the monoclonal antibody of claim 2 or 4 and further comprising additional reagents for a double antibody sandwich assay.
12. The double antibody sandwich kit according to claim 11 wherein the monoclonal antibody of claim 4 is labeled with biotin as a detection antibody and the monoclonal antibody of claim 2 as a capture antibody.
13. The double antibody sandwich kit of claim 12 wherein the capture antibody is coated on an enzyme label plate.
14. The double antibody sandwich kit of claim 12 wherein the optimal coating amount of capture antibody is 2 μ g/well and the working concentration of detection antibody is 2 μ g/ml.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211463230.2A CN115505575B (en) | 2022-11-16 | 2022-11-16 | Two hybridoma cell strains secreting canine IL-31 monoclonal antibody and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211463230.2A CN115505575B (en) | 2022-11-16 | 2022-11-16 | Two hybridoma cell strains secreting canine IL-31 monoclonal antibody and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115505575A true CN115505575A (en) | 2022-12-23 |
| CN115505575B CN115505575B (en) | 2023-03-24 |
Family
ID=84514554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211463230.2A Active CN115505575B (en) | 2022-11-16 | 2022-11-16 | Two hybridoma cell strains secreting canine IL-31 monoclonal antibody and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115505575B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101522713A (en) * | 2006-09-01 | 2009-09-02 | 津莫吉尼蒂克斯公司 | Variable region sequences of IL-31 monoclonal antibodies and methods of use |
| CN103890009A (en) * | 2011-07-21 | 2014-06-25 | 佐蒂斯有限责任公司 | Interleukin-31 monoclonal antibody |
| CN110563844A (en) * | 2019-09-04 | 2019-12-13 | 华中农业大学 | Polyclonal antibody against canine interleukin 31 receptor and application thereof |
| CN114829397A (en) * | 2019-12-20 | 2022-07-29 | 英特维特国际股份有限公司 | Bispecific caninized antibodies for the treatment of atopic dermatitis |
-
2022
- 2022-11-16 CN CN202211463230.2A patent/CN115505575B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101522713A (en) * | 2006-09-01 | 2009-09-02 | 津莫吉尼蒂克斯公司 | Variable region sequences of IL-31 monoclonal antibodies and methods of use |
| CN103044550A (en) * | 2006-09-01 | 2013-04-17 | 津莫吉尼蒂克斯公司 | IL-31 monoclonal antibodies and methods of use |
| CN103890009A (en) * | 2011-07-21 | 2014-06-25 | 佐蒂斯有限责任公司 | Interleukin-31 monoclonal antibody |
| CN110563844A (en) * | 2019-09-04 | 2019-12-13 | 华中农业大学 | Polyclonal antibody against canine interleukin 31 receptor and application thereof |
| CN114829397A (en) * | 2019-12-20 | 2022-07-29 | 英特维特国际股份有限公司 | Bispecific caninized antibodies for the treatment of atopic dermatitis |
| CN114829396A (en) * | 2019-12-20 | 2022-07-29 | 英特维特国际股份有限公司 | Bispecific caninized antibodies and bispecific binding partners for the treatment of atopic dermatitis |
Non-Patent Citations (3)
| Title |
|---|
| SOHEI OYAM: "Cynomolgus monkey model of interleukin-31-induced scratching depicts blockade of human interleukin-31 receptor A by a humanized monoclonal antibody", 《 EXPERIMENTAL DERMATOLOGY》 * |
| YUXIN ZHENG: "Development and characterization of a novel mouse anti-canine oncostatin M receptor beta monoclonal antibody", 《BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS》 * |
| 向娟: "IL-31及其受体在特应性皮炎发病中的作用", 《国际皮肤性病学杂质》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115505575B (en) | 2023-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Berner et al. | Elevated levels of lipopolysaccharide-binding protein and soluble CD14 in plasma in neonatal early-onset sepsis | |
| AU2016201196B2 (en) | Assays for detecting neutralizing autoantibodies to biologic therapy with TNF alpha | |
| US20030124624A1 (en) | Monoclonal antibody and method and kit for immunoassay of soluble human ST2 | |
| US10126312B2 (en) | Diagnostic method for urinary tract infection | |
| JPS6357599A (en) | Canine heart filaria vaccine and diagnostic test | |
| Delhaes et al. | Serum markers for allergic bronchopulmonary aspergillosis in cystic fibrosis: State of the art and further challenges | |
| KR20150088890A (en) | Assays for detecting neutralizing autoantibodies to biologic therapy | |
| CN112142841B (en) | Novel anti-human IL-17A monoclonal antibody, kit containing same and detection method thereof | |
| CN114349858B (en) | Anti-human interleukin-10 high-affinity rabbit monoclonal antibody and application thereof | |
| Kajikawa et al. | Sensitive and specific immunoassays to detect rabbit IL-8 and MCP-1: cytokines that mediate leukocyte recruitment to the lungs | |
| CN115505575B (en) | Two hybridoma cell strains secreting canine IL-31 monoclonal antibody and application thereof | |
| CN115925963B (en) | Bispecific antibodies that bind HBP | |
| CA2924405C (en) | Biomarkers for tuberculosis | |
| CN110726837A (en) | ELISA detection kit for fasciolopsis diagnosis and application thereof | |
| CN1234730C (en) | Mouse antichloromycetin monoclonal antibody and its use | |
| CN112300285B (en) | Enzyme-linked immunoassay method for quantitatively detecting content of anti-human interleukin 17 monoclonal antibody in serum | |
| Ding et al. | A novel ELISA method to determine human MrgX2 in chronic urticaria | |
| Ota et al. | Upregulation of plasma CCL8 in mouse model of graft-vs-host disease | |
| RU2652876C1 (en) | Recombinant antibody specific to tumor nucleus factor and myeloid immune cell marker | |
| Schäfer et al. | Monoclonal antibodies to guinea pig interferon-gamma: tools for cytokine detection and neutralization | |
| CN116286667A (en) | Monoclonal antibody against human IL-17A protein and application thereof | |
| CN115873112B (en) | Procalcitonin antibody and application thereof | |
| CN116063482B (en) | C-reactive protein (CRP) urine detection kit | |
| CN117327186B (en) | Bispecific antibodies that bind MMP3 proteins and uses thereof | |
| CN115975025B (en) | C-reactive protein (CRP) detection kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |